LDN: An Old Drug that Regulates the Immune System

Wednesday 11th November, 05:30pm

Sold out

LDN: An Old Drug that Regulates the Immune System

An Interview with Linda Elsegood

11th November at 5:30PM UK TIME
A comprehensive examination of Low Dose Naltrexone—a little-known drug with big potential.

A drug that is simultaneously affordable, devoid of severe side effects, and applicable to a wide range of diseases is not often found in the modern pharmaceutical landscape. But as medical professionals and researchers alike continue to discover, Low Dose Naltrexone (LDN) boasts this remarkable combination.

LDN, originally prescribed in higher doses as a treatment for opioid addiction, works by blocking opioid receptors, thereby stimulating the production of endorphins, mitigating the inflammatory process, and stabilizing the immune response. Prescribed off-label and administered in small daily doses, this generic drug has proven useful in treating many different ailments.

Expanding on the information presented in The LDN Book, Volume 1—which showcased LDN’s efficacy in treating conditions such as lupus, thyroiditis, autism spectrum disorder, and chronic fatigue—Volume 2 highlights the latest clinical trials, case studies, and research on LDN. More than a dozen medical professionals explain how they are using LDN to help patients suffering from chronic pain, Parkinson’s disease, dermatologic conditions, traumatic brain injury, Lyme disease, and more.

The LDN Book, Volume 2 is both a resource for practitioners, pharmacists, and patients, and a renewed call for further research on the healing potential of this generic drug.

Join us for this exciting interview with Linda Elsegood on understanding the potential of this new drug


Linda Elsegood

Founder of LDN Research Trust

Linda Elsegood founded the LDN Research Trust as a U.K. nonprofit registered charity in 2004, after her success with Low Dose Naltrexone (LDN).  The primary aim of the Trust is to initiate clinical trials of Low Dose Naltrexone for autoimmune diseases and cancers. She was diagnosed with multiple sclerosis (MS) in August 2000 at the age of 44, but my MS can now be traced back to when I was 32 or younger. This led her to create www.ldnresearchtrust.org. The website now features lists of clinical trials and studies involving LDN, conditions for which LDN is used, global LDN prescribers and pharmacists, prescriber/patient guides, and more. The LDN Research Trust is run purely by volunteers; we receive no funding and rely on donations, they work closely with prescribers, pharmacists, and patients, offering support and education. The website is www.ldnresearchtrust.org